Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title: Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Status Recruiting

Clinical Trial Summary

Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.

They will receive salt replacement to correct the acid-base disturbance and possibly their ventilation.

Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and sleep-wake pattern (actigraphy) will be carried out.

Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis.

Clinical Trial Description

Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns and daytime activity level. This would avoid unnecessary treatment with non-invasive ventilation.

Hypothesis: Volume and NaCl replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis and results in symptomatic improvement.

Entry criteria:

• Adult cystic fibrosis patient

• Admission with acute exacerbation

• PaCO2 > 45 mmHg

• Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)

• Serum chloride (Cl) ≤ 98 mmol/L

• Serum albumin (alb) > 25 mmol/L

Intervention:

• Normal saline intravenously day(D)1,2,3. (Replace greater of Cl deficiency or acute weight loss, with 2/3 on D1 and remainder D2, D3)

• NaCl tablets 3 tds D4 to 10 (calculated to replace 7 mmol NaCl loss in 60 kg subject)

Random allocation to either:

1. Intervention + standard care (including standard dietary advice) D1-10

2. Standard care alone (including standard dietary advice) D1-10

Primary outcome measures: (D1, D4, D10)

• PaCO2 (performed at same time of day as admission ABG’s)

• Acid-base status (Stinebaugh and Austin, ABG’s)

• Serum chloride

• Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)

Secondary outcome measures: (D1, D4, D10)

• Serum albumin, sodium

• Body mass index (BMI)

• Spirometry (D1, D10)

• Headache scale

• Epworth sleepiness scale

• Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)

• Urinary chloride, potassium, sodium, pH, osmolality

• Baseline ABG’s as stable outpatient (within 3 months, pre or post admission) ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alkalosis
• Cystic Fibrosis
• Fibrosis

• NCT number: NCT00163852
• Study type: Interventional
• Source: Bayside Health
• Contact: Alan C Young, MBBS, FRACP
• Phone: 613 9276 2000
• Email: alan.young@med.monash.edu.au
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: February 2004
• Completion date: February 2006